Company news
Adaptogenics Health Corp. (CSE:ADPT) news
Adaptogenics Health Corp. news releases on 6ix. Latest, Oct 2, 2026: Adaptogenics Appoints Accomplished Peptide Scientist Dr. J. David Warren as Chief…
Press releases & updates
Adaptogenics Appoints Accomplished Peptide Scientist Dr. J. David Warren as Chief Executive Officer
October 2, 2026
Adaptogenics Health Corp. Announces Closing of Over Subscribed Non-Brokered Private Placement
September 28, 2026
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
September 25, 2026
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
September 17, 2026
Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
September 1, 2026
Adaptogenics Health Corp. Announces Non-Brokered Private Placement
August 14, 2026
Adaptogenics Health Corp. Announces Change of Directors
August 5, 2026
Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
July 29, 2026
Adaptogenics Health Corp. Announces Effective Date of Share Consolidation
July 14, 2026
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
July 9, 2026
Adaptogenics Health Corp. Announces Share Consolidation
July 8, 2026
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
June 17, 2026
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
June 15, 2026
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
May 29, 2026
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
May 5, 2026
Adaptogenics Health Corp. Announces Strategic Review of Health & Wellness Opportunities and Management Changes
May 1, 2026
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
April 15, 2026
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results
February 5, 2026
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
January 27, 2026
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
January 22, 2026
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
January 12, 2026
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 30, 2025
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
December 15, 2025
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease
December 9, 2025
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
December 6, 2025
Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting
November 24, 2025
Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results
November 5, 2025
Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025
October 15, 2025
Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
August 27, 2025
Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results
August 5, 2025
Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025
July 15, 2025
Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®
July 1, 2025
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
May 30, 2025
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
May 28, 2025
Adaptive Biotechnologies Reports First Quarter 2025 Financial Results
May 1, 2025
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025
April 10, 2025
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma
April 8, 2025
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma
March 11, 2025
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results
February 11, 2025
Adaptogenics Health Corp. Signs Letter of Intent with Pulmonem Inc. for Proposed Reverse Takeover Transaction
November 8, 2024
CSE Bulletin: New Listing - Adaptogenics Health Corp. (ADPT)
January 6, 2023
DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders of Adeptus Health Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 9, 2017 - ADPT
May 8, 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Adeptus Health, Inc. of Class Action Lawsuit and Upcoming Deadline - ADPT
May 5, 2017
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Adeptus Health Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 9, 2017 - ADPT
May 4, 2017
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Adeptus Health Inc. (ADPT) and Lead Plaintiff Deadline: May 9, 2017
May 2, 2017
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Adeptus Health Inc. (ADPT) and Lead Plaintiff Deadline: May 9, 2017
April 28, 2017